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Background: Recent evidence demonstrates that high doses of epoetin-alpha
(EPO-α) can be administrated at extended intervals, despite its relatively short
serum half-life. However, no prospective randomized trials on the effects of
extended dosing intervals of EPO-α compared with darbepoetin-alpha (DA-α) have
been performed. This study was designed to investigate whether a single biweekly
(Q2W) administration of a high dose of EPO-α is as effective as DA-α for anemia in
chronic kidney disease (CKD) patients not receiving dialysis.
Methods: Sixty non-dialysis CKD patients were equally randomized to either Q2W
subcutaneous EPO-α (10,000 unit) or DA-α (50 μg) therapy groups for the ﬁrst
6 weeks. After a 6-week washout period, the participants of the EPO-α and DA-α
treatment groups switched to the alternate regimen for 6 weeks. The mean
hemoglobin (Hb) levels after erythropoiesis stimulating agent (ESA) therapy and
percentage change in Hb levels from baseline to the end of the study were analyzed.
Results: The mean Hb levels of postESA therapy increased signiﬁcantly compared
with those of preESA therapy in both ESA regimens. The percentage increase in Hb
levels and erythropoietin resistance index did not show a signiﬁcant difference
between the different ESA regimens. No difference was observed between the
regimens regarding mean Hb levels after ESA therapy. Additionally, there were no
serious adverse effects leading to withdrawal from treatment.
Conclusion: Biweekly high doses of EPO-α therapy may be equally as effective as
Q2W DA-α therapy in maintaining target Hb levels in non-dialysis CKD patients.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license




y to this work.Introduction
Anemia is a well-known, independent risk factor for cardio-
vascular disease in patients with chronic kidney disease (CKD)
[1–3]. If left untreated, the anemia of CKD can result in the
deterioration of cardiac function, decreased cognition, mentalshed by Elsevier. This is an open access article under the CC BY-NC-ND
Na et al / Extended dosing of EPO-α in CKD 211acuity, fatigue, and other signs and symptoms. Furthermore,
anemia of CKD is associated with an increased risk of morbidity
and mortality, principally due to cardiac disease and stroke
[4,5]. Consequently, anemia remains a signiﬁcant problem in
patients with CKD who do not yet require dialysis.
Correction of renal anemia with erythropoiesis-stimulating
agents (ESAs) in non-dialysis CKD patients may provide
potential beneﬁts including the improvement of patient out-
comes. [4–8]. Thus, it is important to manage renal anemia
using ESAs, including short-acting ESAs, darbepoetin-alpha
(DA-α), and methoxy polyethylene glycol-epoetin-beta (con-
tinuous erythropoiesis receptor activator, CERA), in non-
dialysis CKD patients. However, there is no evidence that any
one ESA is superior to another in terms of patient outcomes.
Therefore, the 2012 Kidney Disease: Improving Global Out-
comes (KDIGO) Clinical Practice Guideline for Anemia in CKD
recommended choosing an ESA based on a number of different
aspects such as the balance of pharmacodynamics, safety
information, clinical outcome data, cost, and availability [5].
The frequency of ESA administration should be determined
based on CKD stage, treatment setting, efﬁcacy considerations,
patient tolerance and preference, and type of ESA [5]. The need for
frequent dosing of short-acting ESAs can be a considerable burden
on both patients and health care staff, and it may contribute to the
undertreatment of anemia in nondialysis CKD patients. Because
undertreatment of anemia may contribute to poor outcomes,
patients’ compliance is not a minor problem in managing anemia
in nondialysis CKD patients. In terms of patients’ compliance,
long-acting ESAs such as DA-α and CERA have some advantages
over short-acting epoetin-alpha (EPO-α) [9,10].
The longer half-life enables DA-α to effectively maintain target
hemoglobin levels with less frequent dosing. The extended
dosing interval of once weekly or once every 2 weeks offers
many potential beneﬁts to both patients and health care staff
[11,12]. In comparison, the efﬁcacy of EPO-α decreases when the
dosing intervals are extended to a once-weekly or biweekly
administration. However, there is increasing evidence that a
higher dose of EPO-α can be administrated at extended dosing
intervals while maintaining its efﬁcacy, despite its relatively short
serum half-life [13–16]. Our previous open-label, single-arm
study also showed the beneﬁcial effect of high dose EPO-α at
extended intervals in nondialysis CKD patients [17]. However, to
date, there have been no randomized, crossover trials comparingFigure 1. Study design. The eligible patients were equally randomized to
therapy (Group 1) or a single biweekly subcutaneous epoetin-α (10,000 unit
washout period, patients switched to the alternate ESA regimen for the ne
monthly during the study period. DA-α, darbepoetin-α; EPO-α, epoetin-α; Ea single biweekly administration of high EPO-α with DA-α in
nondialysis CKD patients.
Therefore, we designed a randomized study to investigate
whether a single biweekly high dose of EPO-α is as effective as
a single biweekly equivalent dose of DA-α in correcting anemia
in nondialysis CKD patients.Methods
This study was conducted as an open-label, prospective,
randomized, crossover trial. Adult nondialysis CKD patients were
recruited from three hospitals between May 2009 and December
2009. The inclusion criteria were: (1) adult CKD patients (Z18
years) who did not require dialysis; (2) glomerular ﬁltration rate
(GFR) r60mL/min/1.73 m2, calculated by using the abbreviated
Modiﬁcation of Diet in Renal Disease (MDRD) Study equation;
(3) hemoglobin (Hb) r11 g/dL; (4) adequate iron status: serum
ferritin Z100 ng/mL or transferrin saturation (TSAT) Z20%; and
(5) patients not receiving ESAs for at least 6 weeks prior to
randomization. Patients who had any of the following criteria
were excluded: (1) nonrenal cause of anemia; (2) pure red cell
aplasia; (3) RBC transfusions within the 8 weeks prior to the
study; (4) current active malignancy; (5) poorly controlled
diabetes (HbA1C 410.0%); (6) poorly controlled hypertension
(systolic blood pressure, SBP 4170 mmHg); (7) intact
parathyoid hormone (i-PTH) 4500 pg/mL; (8) congestive heart
failure (NYHA class IV); or (9) pregnancy. Patients werewithdrawn
from the study if there were any serious adverse effects during the
study period; if the patient requested withdrawal; if the ESA dose
was missed425% of a scheduled dose; or if the Hb increa-
sed412.0 g/dL.
The study was approved by the Institutional Review Board of
the Konkuk University Medical Center (IRB approval number:
KUH1010126). After informed consent had been obtained, eligible
patients were equally randomized to receive either a single
biweekly (Q2W) subcutaneous DA-α (50 μg) therapy (Group 1)
or Q2W subcutaneous EPO-α (10,000 unit) therapy (Group 2) for
the ﬁrst 6 weeks (ESA period-1). After a 6-week washout period,
patients switched to the alternate ESA regimen for an additional
consecutive 6 weeks (ESA period-2). Laboratory and patient data
were collected monthly during the study period. Final data
collections were performed at 20 weeks (Fig. 1).receive either a single biweekly subcutaneous darbepoetin-α (50 μg)
) therapy (Group 2) for the ﬁrst 6 weeks (ESA period-1). After a 6-week
xt 6 weeks (ESA period-2). Laboratory and patient data were collected
SAs, erythropoiesis-stimulating agents.
Table 1. Demographics, clinical characteristics, and baseline laboratory





Number of patients (n) 31 29
Gender (male:female) 16:15 11:18
Age (y) 58.8712.5 62.4711.8
DM 20 (64.5) 15 (51.7)
Body weight (kg) 64.7712.4 60.3711.6
Height (cm) 160.778.7 157.677.7
Systolic BP (mmHg) 142.0714.9 137.2717.1
eGFR-MDRD
(mL/min/1.73 m2) 22.979.9 24.179.5
Serum Cr (mg/dL) 3.471.1 3.571.3
Kidney Res Clin Pract 33 (2014) 210–216212ESAs used in this study were Espogen (10,000 unit, preﬁlled
syringe; LG Life Sciences Inc., Seoul, Korea) and Aranesp (50 μg,
preﬁlled syringe; Amgen Inc., Thousand Oaks, CA, USA). The
dose of EPO-α was determined based on the standard conver-
sion rate, 200 IU of EPO-α to 1 μg of DA-α [18,19].
Statistical analyses
The primary efﬁcacy endpoint was the mean Hb level after
ESA therapy. In addition, the efﬁcacy analysis also compared
the percent change of Hb concentration from the baseline and
the end of evaluation periods and the erythropoietin resis-
tance index (ERI), calculated as the weekly weight-adjusted
dose of erythropoietin (U/kg/week) divided by Hb concentra-
tion (g/dL). [20,21].
The sample size was calculated to compare the erythro-
poietic effects of a single biweekly dose of EPO-α with those of
DA-α. It was estimated that a sample size of 65 participants
would provide 80% power to demonstrate that a single
biweekly EPO-α dose is similarly effective to DA-α at an overall
2-sided signiﬁcance level of 0.05 (95.0% CI).
Statistical analysis was performed using SPSS for Window
version 18.0 (SPSS Inc., Chicago, IL, USA). Data were expressed
as mean7standard deviation. The differences between groups
were examined using the Student t test for nonpaired samples.
Changes from baseline to the last follow-up were compared
using the paired t test. Values of Po0.05 were considered to
indicate statistical signiﬁcance.Hemoglobin (g/dL) 9.570.9 9.771.0
Serum ferritin (ng/mL) 157.57138.0 180.07189.6
Transferrin saturation (%) 27.0710.5 29.1713.5
hs-CRP (mg/dL) 0.3370.68 0.1370.17
i-PTH (pg/mL) 139.9782.9 138.3798.5
Data are presented as mean7SD, unless otherwise indicated.
BP, blood pressure; Cr, creatinine; DA-α, darbepoetin-α; eGFR, estimated
glomerular ﬁltration rate; e-GFR-MDRD, estimated glomerular ﬁltration
rate using Modiﬁcation of Diet (MDRD) in Renal Disease formula; EPO-α,
epoetin-α; hs-CRP, high-sensitivity C-reactive protein; i-PTH, intact
parathyroid hormone; SD, standard deviation.Results
Patients’ demographics and clinical characteristics
A total of 74 individuals were assessed for eligibility and 14
of these failed to meet the eligibility criteria. A total of 60
participants were randomized to either a single biweekly dose
of DA-α (Group 1, n¼31) or a single biweekly dose of EPO-αFigure 2. Flow chart of extended dosing schedule of a single biweekl
darbepoetin-α in nondialysis chronic kidney disease patients. The diagratherapy (Group 2, n¼29). A total of 54 (90.0%) individuals
completed the study and six (10.0%) withdrew (Fig. 2). No
statistically signiﬁcant differences were observed in baseline
demographics, clinical characteristics, and laboratory values,
including Hb levels, serum ferritin, transferrin saturation,
high sensitivity C-reactive protein (hs-CRP), and i-PTH,
between the groups (Table 1).The erythropoietic effects of ESAs
Fig. 3 shows the changes of Hb concentration from baseline to
the end of ESA therapy during the study period. In the ESA
period-1, Hb levels of postESA therapy increased signiﬁcantlyy high dose (10,000 units) of epoetin-α and equal dose (50 μg) of
m shows a prospective crossover trial with randomized allocation.
Figure 3. Change in hemoglobin (Hb) concentration from baseline to the end of ESA therapy during study period. Hb levels of postESA therapy
increased signiﬁcantly compared with those of preESA therapy in both groups. There was no statistically signiﬁcant difference in the mean Hb levels
of postESA therapy between the groups. DA-α, darbepoetin-α; EPO-α, epoetin-α; ESA, erythropoiesis-stimulating agent.
Figure 4. Percentage changes in hemoglobin (Hb) levels during study period. The percentage increase in Hb levels after erythropoiesis-
stimulating agent (ESA) therapy did not show a signiﬁcant difference between ESA regimens in ESA period-1 and -2. In addition, there was no
difference in the percentage decrease in Hb levels during the washout period.
Na et al / Extended dosing of EPO-α in CKD 213compared with those of preESA therapy in both groups (Group 1:
preDA-α vs. postDA-α, 9.570.9 g/dL vs. 10.871.2 g/dL, Po0.001;
Group 2: preEPO-α vs. postEPO-α, 9.670.9 g/dL vs. 10.371.3 g/
dL, P¼0.002). There was no statistically signiﬁcant difference in
the mean Hb levels of postESA therapy between the two groups
in the ESA period-1 (postDA-α vs. postEPO-α, 10.871.2 g/dL vs.
10.371.3 g/dL, P¼0.052). The percentage increase in Hb levels
after ESA therapy also did not show a signiﬁcant difference
between the ESA regimens (DA-α vs. EPO-α, 14.0 ± 15.6% vs. 8.4 ±
9.9%, P¼0.072) (Fig. 4). The erythropoietin resistance index also
did not show a signiﬁcant difference between the two groups
during the ESA period-1 (DA-α vs. EPO-α, 8.071.7 IU/kg weight/g
Hb vs. 7.971.8 IU/kg weight/g Hb, P¼0.744).
However, during the washout period, Hb levels decreased
signiﬁcantly in both groups, but no signiﬁcant difference wasobserved between the groups for the mean Hb levels at the
end of the washout period (Group 1 vs. Group 2, 9.870.9 mg/
dL vs. 9.670.9 mg/dL, P¼0.291). There was also no difference
in the percentage decrease in Hb levels during the washout
period (Group 1 vs. Group 2, 7.0711.0% vs. 7.779.0%,
P¼0.808; Fig. 4).
After the washout period, the mean Hb levels of postESA
therapy increased signiﬁcantly compared with those of preESA
therapy in both groups during the ESA period-2 (Group 1:
preEPO-α vs. postEPO-α, 9.870.9 g/dL vs. 10.371.2 g/dL,
Po0.001; Group 2: preDA-α vs. postDA-α, 9.670.9 g/dL vs.
10.771.2 g/dL, Po0.001). There was no statistically signiﬁcant
difference in Hb levels postESA therapy between the two groups
in the ESA period-2 (postDA-α vs. postEPO-α, 10.570.9 g/dL vs.
10.471.2 g/dL, P¼0.739; Fig. 4). The percentage increase in Hb
Kidney Res Clin Pract 33 (2014) 210–216214levels after ESA therapy also did not show a statistically
signiﬁcant differences between the groups (DA-α vs. EPO-α,
11.4 ± 10.4% vs. 6.3 ± 9.1%, P¼0.067). In addition, the two
groups had similar values of the erythropoietin resistance index
during the ESA period-2 (DA-α vs. EPO-α, 7.671.9 IU/kg weight/
g Hb vs. 8.372.0 IU/kg weight/g Hb, P¼0.181).
Overall, the mean Hb levels of postESA therapy increased
signiﬁcantly compared with those of preESA therapy in both
ESA regimens (DA-α, 9.570.9 g/dL vs. 10.771.2 g/dL,
Po0.001; EPO-α, 9.670.9 g/dL vs. 10.371.2 g/dL, P¼0.002).
At 20 weeks, the mean end of study Hb levels were similar in
both ESA regimens (postDA-α vs. postEPO-α, 10.771.2 g/dL vs.
10.371.2 g/dL, P¼0.104). The percentage increase in Hb levels
also did not show a signiﬁcant difference between the two ESA
regimens (postDA-α vs. postEPO-α, 12.7 ± 13.5% vs. 7.3 ± 9.8%,
P¼0.489). Both ESA regimens also had similar values of the
erythropoietin resistance index (DA-α vs. EPO-α, 7.971.8 IU/kg
weight/g Hb vs. 8.071.9 IU/kg weight/g Hb, P¼0.683).
Iron
Of the 60 participants, 32 (53.3%) received oral iron during
the study. Most participants were able to maintain adequate
iron stores. Mean baseline and end of study ferritin and TSAT
were similar in both groups (Table 2).
The adverse effects of ESAs
The adverse event proﬁle was similar in both ESA regimens.
A total of 10 (16.6%) participants who received DA-α and 12







End of study 145.87110.9 156.17160.2
TSAT (%)
Baseline 27.0710.5 29.1713.5
End of study 24.5718.4 27.4720.0
Data are presented as mean7standard deviation.
DA-α, darbepoetin-α; EPO-α, epoetin-α; TSAT, transferrin saturation.
Table 3. Adverse events during erythropoiesis-stimulating agent
therapy in intent-to-treat population
No. of patients with adverse events
DA-α EPO-α
Worsening of hypertension 3 3





Serious events that caused
withdrawal of ESA treatment 0 0
Initiated dialysis 0 0
Death 0 0
DA-α, darbepoetin-α; EPO-α, epoetin-α; ESA, erythropoiesis-stimulating
agent.one adverse event during the study period. There were no
adverse events serious enough to cause withdrawal of treat-
ment during the study period (Table 3).Discussion
The current study showed that an extended dosing sche-
dule consisting of a single biweekly high dose of EPO-α was
well-tolerated and was as effective as a single biweekly dose of
DA-α in maintaining Hb levels in CKD patients who do not
require dialysis.
Despite a short serum half-life, which is 30 hours when
administrated subcutaneously, a single biweekly administra-
tion of EPO-α can effectively increase Hb in nondialysis CKD
patients [13,22,23]. A number of prospective studies have
demonstrated the effectiveness and safety of high dose
short-acting ESAwith extended dosing intervals. In the Clinical
Evaluation of PROCRIT® for Maintenance Phase Treatment of
Patients With Anemia Due to Chronic Kidney Disease
(PROMPT) study, 519 CKD patients with renal anemia (baseline
Hb 411 g/dL) were randomly assigned to receive 10,000 units,
20,000 units, 30,000 units, or 40,000 units of subcutaneous
EPO-α every week, 2 weeks, 3 weeks, and 4 weeks, respec-
tively. At the end of the 16-week treatment period, the mean
Hb levels were not signiﬁcantly statistically different and
remained above 11 g/dL in all four groups [24]. Another study
reported that an EPO-α dose of 40,000 units every 4 weeks
was not inferior to EPO-α dose of 20,000 units every 2 weeks
as initial therapy in CKD patients with anemia [25].
In terms of patient outcomes, the crux of the matter is that
the extended dosing intervals usually require a higher dose of
EPO-α. Recent studies suggest that higher doses of ESAs, in
themselves, may be at least partly responsible for an increased
mortality risk in nondialysis CKD patients [26,27]. Increasing
evidence from multiple well-designed prospective rando-
mized trials, the Correction of Hemoglobin and Outcomes in
Renal Insufﬁciency (CHOIR), Cardiovascular risk Reduction by
Early Anaemia Treatment with Epoetin β (CREATE), and Trial to
Reduce Cardiovascular Events with Aranesp Therapy (TREAT)
trials in predialysis CKD patients suggest that Hb levels
approaching the normal range, compared with levels of
moderate anemia, are associated with increased risk of
adverse outcomes [28–30]. In the CHOIR trial, an unadjusted
analysis showed an increased risk of the primary composite
endpoint (death, myocardial infarction, heart failure, or stroke)
at 4 months was associated with both an inability to achieve
target levels and higher doses of EPO-α (420,000 units per
week). However, in an adjusted analysis, only high-dose EPO-α
therapy resulted in an independent increased risk of the
primary composite endpoint (HR 1.57, 95% CI 1.04–2.36) [28].
These results suggest that an increased mortality may be due
to higher ESA doses rather than the higher target Hb level.
Therefore, based upon currently available evidence, it is
usually recommended that the dose of EPO-α does not exceed
20,000 units per week in nondialysis CKD patients.
The KDIGO guidelines suggested that ESAs not be started
among adult nondialysis CKD patients with Hb concentrations
Z10 g/dL and ESAs should generally not be used to maintain Hb
concentrations 411.5 g/dL. In addition, the KDIGO guidelines
also suggested that ESA therapy should be individualized as
some patients may have improvements in quality of life at Hb
Z11.5 g/dL. The suggestion to maintain Hb levels in the 10.0–11.5
Na et al / Extended dosing of EPO-α in CKD 215g/dL range in nondialysis CKD patients is based on the inter-
pretation of the results of the recent prospective randomized
trials, which found that high Hb targets are associated with
adverse outcomes. In the TREAT trial, there was an increased risk
of fatal or nonfatal stroke with DA-α [30]. In the CHOIR trial, a
higher Hb target was associated with a greater risk of progression
of CKD. In addition, there were a signiﬁcantly higher number of
adverse events in the high Hb group in the CHOIR trial. This
difference was primarily due to insigniﬁcant trends in the high
Hb group, including an increased risk of death and hospitaliza-
tion for heart failure. In a secondary analysis of the CHOIR trial,
the increased risk with higher-dose EPO-α was observed in both
the high- and low-target Hb groups [26]. These results suggest
that any adverse effects including an increased mortality may be
due to higher ESA doses rather than a higher Hb level.
With respect to the toxic effects of high-dose ESA therapy, the
results of our prospective randomized study provided important
information: only 5,000 units of EPO-α per week with a single
biweekly subcutaneous administration was as effective as DA-α
in maintaining target Hb levels in nondialysis CKD patients. In
the present study, no differences were observed between the
groups for the primary efﬁcacy endpoint (mean Hb levels after
ESA therapy). Both groups had similar changes in other efﬁcacy
endpoints such as the percentage change of Hb concentration
between the baseline and evaluation periods and the erythro-
poietin resistance index.
Our study had several potential limitations. The main limita-
tion is the relatively short period of evaluation. In the present
study, the follow-up period to evaluate the efﬁcacy of each ESA
regimen was only 8 weeks in the per-protocol population. The
period is too short to reveal a sufﬁcient erythropoietic effect of
ESA and to demonstrate Hb stability. It has been suggested that
at least 16 weeks may be needed to achieve stability of the DA-α
dose and Hb level. Due to the half-life of circulating red blood
cells, which is 60 days in dialysis patients, it is anticipated
that the equilibrium of Hb concentrations after switching from
EPO-α to DA-α would occur within 20–24 weeks. However, a
recent study demonstrated that the median time to a Hb
increase of41 g/dL from baseline ranged from 3 weeks to 5
weeks after extended dosing with EPO-α [13]. Thus, we
expected that the impact of the extended dosing of EPO-α and
DA-α would manifest within 8 weeks. The other limitations in
our study are the relatively small number of participants and
the nonblinded design. However, this study is a randomized,
controlled crossover trial, which has some advantages over a
parallel and a noncrossover longitudinal study. One of its
advantages is that crossover designs are statistically efﬁcient
and so require fewer participants than do noncrossover designs.
The limitation of the relatively small number of participants is
partially overcome by the randomized, controlled crossover
design of the present study.
In conclusion, our study demonstrated that a single
biweekly high dose of EPO-α therapy may be as effective as a
single biweekly dose of DA-α therapy in maintaining target Hb
levels in nondialysis CKD patients with renal anemia. Further
randomized controlled trials are necessary to clarify the long-
term clinical beneﬁts and adverse effects of extended dosing of
EPO-α treatment in CKD patients who are not on dialysis.Conﬂict of interest
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